Related Experiment Video

Updated: Feb 24, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy

Manuela Schmidinger1, Christoph C Zielinski

  • 1Department of Medicine I and Cancer Center, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

Cancer Treatment Reviews
|February 24, 2009
PubMed

Insights

Selecting first-line therapy for metastatic renal cell carcinoma (RCC) is complex. Bevacizumab with interferon (IFN) may offer cure, while sunitinib and bevacizumab with IFN provide similar progression-free survival (PFS) for RCC patients.

Area of Science:

  • Oncology
  • Medical Therapeutics

Background:

  • First-line treatment options for metastatic renal cell carcinoma (RCC) have expanded with new agents like sunitinib, temsirolimus, and bevacizumab with interferon (IFN).
  • Selecting optimal therapy for individual metastatic RCC patients is challenging due to increased treatment choices.
  • Current treatment algorithms based on histology and risk status may not fully personalize treatment for all patients, especially those with favorable or intermediate risk clear cell RCC.

Purpose of the Study:

  • To guide the selection of optimal first-line therapy for metastatic renal cell carcinoma (RCC) patients.
  • To evaluate treatment considerations including potential for cure, progression-free survival (PFS), tolerability, and quality of life.
  • To analyze patient-related factors and side effect profiles of sunitinib and bevacizumab with IFN for personalized treatment decisions.

Main Methods:

  • Review of available data on novel first-line therapies for metastatic RCC.
  • Comparison of treatment outcomes including progression-free survival (PFS) and potential for cure.
  • Analysis of patient-specific factors, comorbidities, and side effect profiles of sunitinib and bevacizumab with IFN.

Main Results:

  • Bevacizumab in combination with interferon (IFN) may be considered for patients with a realistic opportunity for cure in metastatic renal cell carcinoma (RCC).
  • Sunitinib and bevacizumab with IFN demonstrate comparable progression-free survival (PFS) in metastatic RCC.
  • Patient-related factors and side effect profiles are crucial for selecting between sunitinib and bevacizumab with IFN when optimal PFS is the goal.

Conclusions:

  • Treatment selection for metastatic RCC requires balancing potential for cure, PFS, tolerability, and patient-specific factors.
  • Bevacizumab with IFN and sunitinib are key first-line options, with individual patient characteristics guiding the choice.
  • Further consideration of patient needs and side effect profiles is essential for optimizing metastatic RCC treatment strategies.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.3K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K